Indication: Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis. In amebic liver abscess, METRONIDAZOLE, USP therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of METRONIDAZOLE, USP and other antibacterial drugs, METRONIDAZOLE, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.